Gland Pharma Limited share price
NSE: GLAND · ISIN INE068V01023
Key numbers
- Market cap
- ₹ 48,137 Cr
- Current price
- ₹ 2,917.20
- 52-week high / low
- ₹ 3,042 / 1,574
- Stock P/E
- 42.6
- Book value
- ₹ 628.7
- Dividend yield
- 0.69%
- ROCE
- 14.9%
- ROE
- 10.5%
- Debt to equity
- 0.03
- Sales growth (3 yrs)
- 21.3%
- Profit growth (3 yrs)
- 9.6%
- 1-year return
- 44.6%
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,425 | 1,506 | 1,695 | 1,743 | 1,800 |
| Operating profit | 348 | 368 | 435 | 513 | 489 |
| Net profit | 187 | 215 | 261 | 367 | 317 |
| EPS (₹) | 11.32 | 13.08 | 15.87 | 22.26 | 19.23 |
Concall summary (2026-08-17)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Other income, comprising primarily interest income, stood at INR612 million in Q1 FY26 [Correction: Q1 FY27].
- During the quarter, there was a forex loss of INR36 million, which is included in other expense as compared to forex gain of INR508 million in Q4 FY26 and INR39 million in Q1 FY26 included in other income.
Growth & demand
- Growth during the quarter was driven by continuous contributions from recently launched products, expansion in CDMO revenue and continued volume growth in existing products.
- So if you look at the market growth versus our growth in the U.S., it's always far higher than the market growth because of the new launches what we do and also the current products what is secured by others, we're able to garner those -- that market share to us because of a better cost structure.
Margins & costs
- Adjusted EBITDA for this quarter stood at INR5,102 million with margins of 28%, while profit after tax was INR3,170 million, reflecting a healthy growth of 47% year - on-year with PAT margin of 18%.
- Reported EBITDA for the quarter stood at INR4,930 million with EBITDA margin GLAND] Gland Pharma Limited August 10, 2026 platforms.
Capex & expansion
- Building on our recently announced capex program, we are actively progressing multiple brownfield and greenfield expansion initiatives across our manufacturing network.
- We continue to evaluate additional capacity requirements to ensure that we remain well positioned to capture future growth opportunities while maintaining operational flexibility and GLAND] Gland Pharma Limited August 10, 2026 In India, revenues for the quarter stood at INR666 million.
Balance sheet & cash
- Continued operating leverage, improved capacity utilization and disciplined cost management have further supported our pro fitability during the quarter.
- With healthy cash in hand, we are a net cash surplus company with a net cash position of INR32,939 million.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.